With global headquarters in France, Biocodex has expanded its geographic footprint over the past 10 years and today operates through 17 affiliates and long-term partnerships in other countries. Through this international network, Biocodex offers health solutions to patients in more than 115 countries.
Biocodex’s international expansion
Biocodex’s global presence
Biocodex has subsidiaries in Belgium, Canada, Mexico, Morocco, Nordics (Finland, Sweden, Norway, Estonia, Latvia and Lithuania), Poland, Portugal, Russia, Turkey, Ukraine and the United States.
Biocodex has found a balance between building a global network and maintaining a strong local focus. The combination of strategic local investments and selected partnerships has enabled the company to successfully expand worldwide. Our valued subsidiaries, employees and partners play an essential role in meeting our development goals.
Chief Executive Officer at BIOCODEX
Biocodex’s global sales breakdown
Biocodex’s global development
Biocodex’s development is closely linked to employee empowerment, entrepreneurial spirit and agility. We believe teamwork and engagement are as important as strategy.
Our teams are dedicated to strengthening:
- Biocodex’s pillars: the Microbiota Mission, orphan drugs and women’s health
- Our worldwide brands through a strong digital marketing strategy
- Our partnerships with new product developments
Want to know more?
Biocodex is a family-owned company founded more than 60 years ago to market the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Biocodex has since expanded its expertise in gut microbiota, evolving from French pioneer to an international player in the microbiota realm.
Biocodex develops, manufactures and distributes world-class pharmaceutical products and health solutions for patients in more than 120 countries. Focusing on three main pillars (microbiota mission, orphan drugs and women’s health), we combine in house R&D and scientific partnerships, production expertise, and investments in start-ups to remain at the forefront of innovation and quality.
Biocodex is a family-owned multinational pharmaceutical company founded in France in 1953. The initial focus of the company was gastroenterology, featuring a unique probiotic: Saccharomyces boulardii CNCM I-745®, the first probiotic drug to have a positive effect on intestinal microbiota.